Biofarm Sp. z o.o.,Aspicam Bio (Aspicam) tablets 7.5mg 20 tablets,Aspicam Bio (Aspicam) tabl. 7,5mg 20tabl.

Compound:
1 tablet contains 7.5 mg of meloxicam (Meloxicamum).
Excipient with known effect: lactose monohydrate 128.4 mg.
Indications:
As an anti-inflammatory and analgesic, it is used for osteoarticular and muscle pain, and for rheumatoid and degenerative joint diseases.
Apply:
– for short-term treatment of exacerbations of symptoms of rheumatoid diseases, such as:
rheumatoid arthritis, juvenile rheumatoid arthritis and ankylosing spondylitis.
Contraindications.
The use of the drug is contraindicated in the following cases:
− third trimester of pregnancy;
− children and adolescents under 15 years of age;
– hypersensitivity to meloxicam or any of the excipients or substances with similar effects, for example NSAIDs, acetylsalicylic acid; Meloxicam should not be used in patients with symptoms of asthma, nasal polyps, angioedema and urticaria observed after the use of acetylsalicylic acid or other NSAIDs;
– history of gastrointestinal bleeding or perforation of the gastrointestinal tract, causally related to previous treatment with NSAIDs;
− active gastric and/or duodenal ulcer or history of recurrent peptic ulcer and bleeding (two or more separate episodes of confirmed ulceration or bleeding);
− serious liver problems;
− severe renal failure in patients not on dialysis;
– history of bleeding from the gastrointestinal tract, cerebral bleeding or other bleeding disorders;
− severe heart failure.
Side effects:
a) General description
Clinical and epidemiological studies indicate that some NSAIDs (especially long-term use and high doses) are associated with a slightly increased risk of arterial embolism (eg, heart attack or stroke).
Cases of edema, hypertension and heart failure have been reported in association with NSAID treatment.
The most commonly observed side effects come from the gastrointestinal tract. Peptic ulcers, perforation, or bleeding from the gastrointestinal tract may occur, sometimes fatal, especially in older people. During treatment, nausea, vomiting, diarrhea, flatulence, constipation, dyspeptic symptoms, abdominal pain, melena, hematemesis, ulcerative stomatitis, exacerbation of ulcerative colitis and Crohn’s disease were observed. Gastritis has been reported less frequently.